Castration-resistant Prostate Cancer

• CLINICAL_TRIALS trial_result · 2025-01-29
  Clinical Trial Update: Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer [Phase 2]

  Phase II study evaluating olaparib, a PARP inhibitor, with intravenous ascorbate for castration-resistant prostate cancer; the trial is term…

• CLINICAL_TRIALS research · 2025-01-24
  Clinical Trial Update: ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

  A Phase 2 randomized trial evaluating ZEN003694 in combination with enzalutamide versus enzalutamide monotherapy in metastatic castration-re…

• CLINICAL_TRIALS trial_result · 2025-01-24
  Clinical Trial Update: A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

  Phase 2 trial update evaluating SHR3162 with Apatinib or SHR3162 alone in metastatic castration-resistant prostate cancer has completed.

• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy [Phase 4]

  Phase 4 safety and efficacy results for enzalutamide in Indian patients with metastatic castration-resistant prostate cancer previously trea…

• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) [Phase 2]

  Phase 2 trial update of irofulven in metastatic castration-resistant prostate cancer patients previously treated with docetaxel, using a Dru…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer [Phase 1]

  A Phase 1 trial from the University of Michigan evaluates talazoparib in combination with belinostat in metastatic breast cancer, metastatic…

• CLINICAL_TRIALS trial_result · 2025-01-22
  Clinical Trial Update: Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer [Phase 1]

  A Phase 1 trial evaluated oral BIBF 1120 (nintedanib) in combination with docetaxel and prednisone in patients with hormone-refractory prost…

• CLINICAL_TRIALS trial_result · 2025-01-20
  Clinical Trial Update: Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide [Phase 2]

  This Phase 2 trial assesses pembrolizumab in patients with metastatic castration-resistant prostate cancer who were previously treated with …

• CLINICAL_TRIALS research · 2025-01-14
  Clinical Trial Update: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies [Phase 1]

  This Phase 1 trial from Epigenetix, Inc. is evaluating a dual BET and CBP/p300 inhibitor across targeted advanced solid tumors and hematolog…

• CLINICAL_TRIALS trial_result · 2025-01-13
  Clinical Trial Update: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Expanded access treatment with Lu-177-PNT2002 for adults with PSMA-positive metastatic castration-resistant prostate cancer, currently tempo…

• CLINICAL_TRIALS research · 2025-01-10
  Clinical Trial Update: Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC [Phase 3]

  Phase III study evaluating two regimens of abiraterone acetate in metastatic castration-resistant prostate cancer is not yet recruiting.

• CLINICAL_TRIALS trial_result · 2025-01-08
  Clinical Trial Update: Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) [Phase 2]

  Phase 2 study evaluating Radiometabolic Therapy with Lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer has completed.

• CLINICAL_TRIALS research · 2025-01-08
  Clinical Trial Update: Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 1]

  Phase 1 clinical trial investigating cyclophosphamide plus dexamethasone for metastatic castration-resistant prostate cancer; the study is c…

• CLINICAL_TRIALS research · 2025-01-08
  Clinical Trial Update: Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors [NA]

  This clinical trial update notes the completion of a study evaluating PSMA PET/CT as an imaging biomarker in metastatic castration-resistant…

• CLINICAL_TRIALS trial_result · 2025-01-01
  Clinical Trial Update: Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating olaparib in castration-resistant prostate cancer was terminated; results have been posted.

• CLINICAL_TRIALS research · 2024-12-31
  Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 3]

  Phase III multicenter randomized trial evaluating Fuzuloparib in combination with Abiraterone acetate and prednisone versus placebo with Abi…

• CLINICAL_TRIALS research · 2024-12-20
  Clinical Trial Update: Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging [Phase 3]

  Phase 3 trial evaluating darolutamide with or without radiation therapy for metastatic castration-resistant prostate cancer; currently recru…

• CLINICAL_TRIALS trial_result · 2024-12-13
  Clinical Trial Update: A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. [Phase 1]

  A Phase I/Ib trial of NZV930 alone and in combination with PDR001 and/or NIR178 in patients with advanced malignancies has been terminated.

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status [Phase 2]

  Phase 2 trial evaluating Radium-223 in asymptomatic metastatic castration-resistant prostate cancer patients on Abiraterone or Enzalutamide,…

• CLINICAL_TRIALS research · 2024-12-11
  Clinical Trial Update: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating Ga-68-NGUL and Lu-177-DGUL in metastatic castration-resistant prostate cancer is currently active but …

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. [Phase 1, Phase 2]

  The clinical trial update reports termination of the Phase 1/2 study of ONCT-534 in metastatic castration-resistant prostate cancer, and res…

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

  Phase 1/Phase 2 trial update for the radiopharmaceutical 177Lu-LNC1011 in metastatic castration-resistant prostate cancer. The current trial…

• CLINICAL_TRIALS trial_result · 2024-12-10
  Clinical Trial Update: Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]

  Phase 2 multicenter trial evaluating abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer; res…

• CLINICAL_TRIALS research · 2024-12-06
  Clinical Trial Update: Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

  A prospective observational KiRi-Trial investigates kidney function and risk factors in patients with metastatic castration-resistant prosta…

• CLINICAL_TRIALS research · 2024-12-04
  Clinical Trial Update: Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) [Phase 2]

  A Phase 2 clinical trial (PCS X) is investigating management of oligoprogressive metastatic castration-resistant prostate cancer, with recru…